Our Bureau, Mumbai Wednesday, November 13, 2024, 12:15 Hrs [IST] ...

Abbisko announces positive results from phase 3 MANEUVER study of pimicotinib to treat tenosynovial giant cell tumour: Shanghai Wednesday, November 13, 2024, 18:00 Hrs [IST] Abbis ...

Oncoinvent ASA, a clinical stage company advancing alpha emitter therapy across a variety of solid cancers, announced an interim data readout of the phase 1/2a studies of Radspherin for the treatment ...

Aethlon Medical reaches key milestone with enrollment of first patient in its Hemopurifier cancer trial in Australia: San Diego Wednesday, November 13, 2024, 15:30 Hrs [IST] Aethl ...

Arch Biopartners Inc, a late-stage clinical trial company focused on preventing inflammation and acute organ injury, has announced that patient recruitment and dosing have begun in Canada for the ...

KOMET phase III trial of Koselugo shows statistically significant and clinically meaningful ORR vs. placebo in adults with neurofibromatosis type 1: Cambridge, UK Wednesday, Novem ...

Sonoma Pharma receives US FDA 510(k) clearance for Microcyn-based wound care hydrogel: Boulder, Colorado Wednesday, November 13, 2024, 16:00 Hrs [IST] Sonoma Pharmaceuticals, Inc.

AstraZeneca and Daiichi Sankyo have submitted a new Biologics License Application (BLA) for accelerated approval in the US for datopotamab deruxtecan (Dato-DXd) for the treatment of adult patients ...

Tectonic Therapeutic, Inc., a clinical stage biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs, announced ...

ALK, a global specialty pharmaceutical company focused on allergy and allergic asthma, announced that it has entered into a strategic license agreement with US-based ARS Pharmaceuticals, Inc. (ARS ...

Rahway, New Jersey Wednesday, November 13, 2024, 13:00 Hrs [IST] ...

Spring House, Massachusetts Wednesday, November 13, 2024, 14:00 Hrs [IST] ...